Improved mucoadhesion and cell uptake of chitosan and chitosan oligosaccharide surface-modified polymer nanoparticles for mucosal delivery of proteins

Drug Delivery and Translational Research

Volumn 6, Issue 4, 2016, Pages 365-379

  Dyawanapelly, Sathish ^a   Koli, Uday ^a   Dharamdasani, Vimisha ^a   Jain, Ratnesh ^a   Dandekar, Prajakta ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Chitosan; Chitosan oligosaccharide; Mucosal delivery; Nanoparticle; Poly (d, l lactide co glycolide); Protein

Indexed keywords

BOVINE SERUM ALBUMIN; CHITOSAN; CHITOSAN OLIGOSACCHARIDE; CRYOPROTECTIVE AGENT; DRUG CARRIER; NANOPARTICLE; OLIGOSACCHARIDE; POLYGLACTIN; PROTEIN; SOLVENT; UNCLASSIFIED DRUG; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

A549 CELL LINE; ARTICLE; CELL INTERACTION; COMPARATIVE STUDY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOUBLE EMULSION SOLVENT EVAPORATION METHOD; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; MUCOADHESION; MUCOSAL DRUG ADMINISTRATION; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCEDURES; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; METABOLISM; MUCOSA; PHARMACOKINETICS; ULTRASTRUCTURE;

CELL SURVIVAL; CHITOSAN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG LIBERATION; HUMANS; LACTIC ACID; MUCOUS MEMBRANE; NANOPARTICLES; OLIGOSACCHARIDES; PARTICLE SIZE; POLYGLYCOLIC ACID; PROTEINS; SERUM ALBUMIN, BOVINE;

EID: 84979010869     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-016-0295-x     Document Type: Article

References (62)

1. Yadav SC, Kumari A, Yadav R. Development of peptide and protein nanotherapeutics by nanoencapsulation and nanobioconjugation. Peptides. 2011;32(1):173–87.
2. Gu W-X, Zhu M, Song N, Du X, Yang Y-W, Gao H. Reverse micelles based on biocompatible β-cyclodextrin conjugated polyethylene glycol block polylactide for protein delivery. J Mater Chem B. 2015;3(2):316–22.
3. Irie T, Uekama K. Cyclodextrins in peptide and protein delivery. Adv Drug Deliv Rev. 1999;36(1):101–23.
4. Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React Funct Polym. 2011;71(3):280–7.
5. Lu Y, Yang J, Sega E. Issues related to targeted delivery of proteins and peptides. AAPS J. 2006;8(3):E466–78.
6. Stolnik S, Shakesheff K. Formulations for delivery of therapeutic proteins. Biotechnol Lett. 2009;31(1):1–11.
7. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly (D, L-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125(3):193–209.
8. Dong Y, Feng S-S. Poly (d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(30):6068–76.
9. Blanco MD, Alonso MJ. Development and characterization of protein-loaded poly (lactide-co-glycolide) nanospheres. Eur J Pharm Biopharm. 1997;43(3):287–94.
10. Cun D, Foged C, Yang M, Frøkjær S, Nielsen HM. Preparation and characterization of poly (DL-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm. 2010;390(1):70–5.
11. Tahara K, Yamamoto H, Hirashima N, Kawashima Y. Chitosan-modified poly (D, L-lactide-co-glycolide) nanospheres for improving siRNA delivery and gene-silencing effects. Eur J Pharm Biopharm. 2010;74(3):421–6.
12. Kumar MNVR, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25(10):1771–7.
13. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010;6(1):12–21.
14. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem. 2009;17(8):2950–62.
15. Labhasetwar V. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Curr Opin Biotechnol. 2005;16(6):674–80.
16. RaviKumar MNV, Mohapatra SS, Kong X, Jena PK, Bakowsky U, Lehrd CM. Cationic poly (lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents. J Nanosci Nanotechnol. 2004;4(8):990–4.
17. Peniche C, Argüelles-Monal WW, Peniche H, Acosta N. Chitosan: an attractive biocompatible polymer for microencapsulation. Macromol Biosci. 2003;3(10):511–20.
18. Yang R, Shim W-S, Cui F-D, Cheng G, Han X, Jin Q-R, et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm. 2009;371(1):142–7.
19. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62(1):12–27.
20. Ragelle H, Vandermeulen G, Véronique P. Chitosan-based siRNA delivery systems. J Control Release. 2013;172(1):207–18.
21. Köping-Höggård M, Vårum KM, Issa M, Danielsen S, Christensen BE, Stokke BT, et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther. 2004;11(19):1441–52.
22. Richardson SW, Kolbe HJ, Duncan R. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm. 1999;178(2):231–43.
23. Hu F-Q, Liu L-N, Du Y-Z, Yuan H. Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. Biomaterials. 2009;30(36):6955–63.
24. Huang X, Du Y-Z, Yuan H, Hu F-Q. Preparation and pharmacodynamics of low-molecular-weight chitosan nanoparticles containing insulin. Carbohydr Polym. 2009;76(3):368–73.
25. Biswas S, Chattopadhyay M, Sen KK, Saha MK. Development and characterization of alginate coated low molecular weight chitosan nanoparticles as new carriers for oral vaccine delivery in mice. Carbohydr Polym. 2015;121:403–10.
26. Hu F-Q, Zhao M-D, Yuan H, You J, Du Y-Z, Zeng S. A novel chitosan oligosaccharide-stearic acid micelles for gene delivery: Properties and in vitro transfection studies. Int J Pharm. 2006;315(1):158–66.
27. Amoozgar Z, Park J, Lin Q, Yeo Y. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol Pharm. 2012;9(5):1262–70.
28. Murata M, Nakano K, Tahara K, Tozuka Y, Takeuchi H. Pulmonary delivery of elcatonin using surface-modified liposomes to improve systemic absorption: polyvinyl alcohol with a hydrophobic anchor and chitosan oligosaccharide as effective surface modifiers. Eur J Pharm Biopharm. 2012;80(2):340–6.
29. Ying X-Y, Cui D, Yu L, Du Y-Z. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydr Polym. 2011;84(4):1357–64.
30. Liu X, Huang H, Liu G, Zhou W, Chen Y, Jin Q, et al. Multidentate zwitterionic chitosan oligosaccharide modified gold nanoparticles: stability, biocompatibility and cell interactions. Nanoscale. 2013;5(9):3982–91.
31. Bae KH, Park M, Do MJ, Lee N, Ryu JH, Kim GW, et al. Chitosan oligosaccharide-stabilized ferrimagnetic iron oxide nanocubes for magnetically modulated cancer hyperthermia. ACS Nano. 2012;6(6):5266–73.
32. Shukla S, Jadaun A, Arora V, Sinha RK, Biyani N, Jain VK. In vitro toxicity assessment of chitosan oligosaccharide coated iron oxide nanoparticles. Toxic Rep. 2015;2:27–39.
33. Jain S, Datta M. Montmorillonite-PLGA nanocomposites as an oral extended drug delivery vehicle for venlafaxine hydrochloride. Appl Clay Sci. 2014;99:42–7.
34. Gan Q, Wang T. Chitosan nanoparticle as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B: Biointerfaces. 2007;59(1):24–34.
35. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release. 2009;133(1):11–7.
36. Wang G, Yu B, Wu Y, Huang B, Yuan Y, Liu CS. Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel. Int J Pharm. 2013;446(1):24–33.
37. Md S, Khan RA, Mustafa G, Chuttani K, Baboota S, Sahni JK, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci. 2013;48(3):393–405.
38. Parveen S, Sahoo SK. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. Eur J Pharmacol. 2011;670(2):372–83.
39. Philippova OE, Korchagina EV, Volkov EV, Smirnov VA, Khokhlov AR, Rinaudo M. Aggregation of some water-soluble derivatives of chitin in aqueous solutions: role of the degree of acetylation and effect of hydrogen bond breaker. Carbohydr Polym. 2012;87(1):687–94.
40. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials. 2010;31(13):3657–66.
41. Huang P, Li Z, Hu H, Cui D. Synthesis and characterization of bovine serum albumin-conjugated copper sulfide nanocomposites. J Nanomater. 2010;2010:33.
42. Kaewsaneha C, Opaprakasit P, Polpanich D, Smanmoo S, Tangboriboonrat P. Immobilization of fluorescein isothiocyanate on magnetic polymeric nanoparticle using chitosan as spacer. J Colloid Interface Sci. 2012;377(1):145–52.
43. Dandekar P, Jain R, Stauner T, Loretz B, Koch M, Wenz G, et al. A hydrophobic starch polymer for nanoparticle-mediated delivery of docetaxel. Macromol Biosci. 2012;12(2):184–94.
44. Paolicelli P, Prego C, Sanchez A, Alonso MJ. Surface-modified PLGA-based nanoparticles that can efficiently associate and deliver virus-like particles. Nanomedicine. 2010;5(6):843–53.
45. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release. 2009;133(2):90–5.
46. Fonte P, Soares S, Sousa F, Costa A, Seabra V, Reis S, et al. Stability study perspective of the effect of freeze-drying using cryoprotectants on the structure of insulin loaded into PLGA nanoparticles. Biomacromolecules. 2014;15(10):3753–65.
47. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688–713.
48. Sameti M, Bohr G, Kumar MNVR, Kneuer C, Bakowsky U, Nacken M, et al. Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery. Int J Pharm. 2003;266(1):51–60.
49. De Jaeghere F, Allémann E, Feijen J, Kissel T, Doelker E, Gurny R. Freeze-drying and lyopreservation of diblock and triblock poly (lactic acid)-poly (ethylene oxide)(PLA-PEO) copolymer nanoparticles. Pharm Dev Technol. 2000;5(4):473–83.
50. Holzer M, Vogel V, Mäntele W, Schwartz D, Haase W, Langer K. Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm. 2009;72(2):428–37.
51. Prajakta D, Ratnesh J, Chandan K, Suresh S, Grace S, Meera V, et al. Curcumin loaded pH-sensitive nanoparticles for the treatment of colon cancer. J Biomed Nanotechnol. 2009;5(5):445–55.
52. Thasneem YM, Rekha MR, Sajeesh S, Sharma CP. Biomimetic mucin modified PLGA nanoparticles for enhanced blood compatibility. J Colloid Interface Sci. 2013;409:237–44.
53. Ma FK, Li J, Kong M, Liu Y, An Y, Chen XG. Preparation and hydrolytic erosion of differently structured PLGA nanoparticles with chitosan modification. Int J Biol Macromol. 2013;54:174–9.
54. Guo M, Rong W-T, Hou J, Wang D-F, Lu Y, Wang Y, et al. Mechanisms of chitosan-coated poly (lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin. Nanotechnology. 2013;24(24):245101.
55. Pawar D, Mangal S, Goswami R, Jaganathan KS. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur J Pharm Biopharm. 2013;85(3):550–9.
56. Jagani HV, Josyula VR, Palanimuthu VR, Hariharapura RC, Gang SS. Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating. Eur J Pharm Sci. 2013;48(4):611–8.
57. Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine. 2010;28(38):6282–91.
58. He P, Davis SS, Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm. 1998;166(1):75–88.
59. Burton JD. The MTT assay to evaluate chemosensitivity. Chemosensitivity. Springer. 2005. p. 69–78.
60. Grabowski N, Hillaireau H, Vergnaud J, Santiago LA, Kerdine-Romer S, Pallardy M, et al. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. Int J Pharm. 2013;454(2):686–94.
61. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Hirashima N, Kawashima Y. Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells. Int J Pharm. 2009;382(1):198–204.
62. Foster S, Duvall CL, Crownover EF, Hoffman AS, Stayton PS. Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug Chem. 2010;21(12):2205–12.